- Home
- LBRX vs ODTX Comparison
LBRX vs ODTX Comparison
Compare LBRX & ODTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LBRX | ODTX |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | 27 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 958.7M | 794.2M |
| IPO Year | N/A | 2026 |
Fundamental Metrics
Financial Performance| Metric | LBRX | ODTX |
|---|---|---|
| Price | $31.14 | $18.34 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $46.60 | N/A |
| AVG Volume (30 Days) | ★ 351.9K | 296.1K |
| Earning Date | 05-06-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.40 | $15.10 |
| 52 Week High | $35.35 | $20.00 |
Technical Indicators
Market Signals| Indicator | LBRX | ODTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.93 | 49.48 |
| Support Level | $26.75 | $17.45 |
| Resistance Level | $34.10 | $19.59 |
| Average True Range (ATR) | 1.98 | 1.45 |
| MACD | -0.32 | 0.15 |
| Stochastic Oscillator | 31.75 | 67.71 |
Price Performance
Historical ComparisonAbout LBRX LB Pharmaceuticals Inc
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.